

### Indicator: Chronic Opioid Use

Data Source	Definition	Numerator	Denominator	Comments	Covariates
PBS	Proportion of home care recipients who are chronic opioid users.	Number of home care recipients who are chronic opioid users (Table 1). Chronic opioid use is defined as receiving any number of opioid medications for at least 90 days continuously, or for 120 non-consecutive days (1). The number of days of medication use is determined based on the number of units dispensed and estimated dose per day. No gap days between one opioid medication dispensing and another were allowed when determining consecutive use of opioids.	Number of home care recipients.  Exclude pharmacological cancer treatment (Table 2).	N/A.	Age, sex, number of health conditions (excluding pain).

**PBS:** Pharmaceutical Benefits Scheme. **N/A:** Not Applicable.

**Table 1. Opioids Medications, Descriptions, ATC Codes, PBS Codes and Estimated Usual Dose.**

Description	ATC	PBS items	Usual dose per day <sup>1</sup>
Morphine	N02AA01	08491X, 08492Y, 08493B	1
		01653B, 01654C, 01655D, 01656E, 02839K, 02840L, 02841M, 05392T, 05393W, 05394X, 05395Y, 08035X, 08349K, 08453X, 08489T, 08494C, 08669G, 08670H	2
		04349X, 05161P, 05162Q, 05164T, 05165W, 05391R	
		08146R, 08305D, 08306E, 08490W	2 sachets
		01646P	4
		02122Q, 02123R, 02124T, 09014K, 09015L, 09016M, 09017N	30 mg
Hydromorphone	N02AA03	09299K, 09406C, 09407D, 09408E, 09409F	1
		03357Q	
		05132D <sup>2</sup> , 08424J, 11467M	12mL
		08541M, 08542N, 08543P, 12047C, 12497R	6

Oxycodone	N02AA05	08385H, 08386J, 08387K, 08388L, 09399Q, 09400R, 05227D, 05247E, 05248F, 05249G, 05250H, 08681X	2
		05191F, 05195K, 08464L, 08501K, 08502L, 02481N, 02622B, 05197M, 05198N, 12031F, 12023T	4
		05191F <sup>2</sup> , 08644Y, 05190E	20 mL
Oxycodone + Naloxone	N02AA55	08000C, 08934F, 08935G, 08936H, 10757E, 10758F, 10776E, 11102H, 11111T	2
Fentanyl <sup>3</sup>	N02AB03	05265D, 05277R, 05278T, 05279W, 05280X, 05437E, 05438F, 05439G, 05440H, 05441J, 08878G, 08891Y, 08892B, 08893C, 08894D, 08337T, 08338W, 08339X, 08340Y	1 patch per 3 days
Methadone	N02AC52	01609Q	3
Methadone liquid	N02AC52	05399E, 05400F	6 mL
Buprenorphine	N02AE01	08865N, 08866P, 08866P, 08867Q, 10746N, 10755C, 10756D, 10770W, 10948F, 10949G, 10953L, 10957Q, 10959T, 10964C, 10970J, 08867Q	1 patch per 7 days
Codeine, combinations with paracetamol	N02AJ06	01215Y, 03316M, 04170L, 04171M, 04275B, 04286N, 08785J, 10186D, 12022R	8
Tramadol	N02AX02	02527B, 08523N, 08524P, 08525Q, 03338Q, 05234L, 05235M, 05236N	2
		05001F, 091993, 09200F, 09201G	1
		05232J, 08455B, 08611F, 12008B	4
		08582Q, 05231H	4 injection
		08843K	160 drops = 400mg
Tapentadol	N02AX06	10091D, 10092E, 10094G, 10096J, 10100N	2
Codeine	N02AA	05063L, 01214X, 12065B	4

<sup>1</sup>Quantity per day in tablets unless otherwise stated.

<sup>2</sup>Removed from the PBS in 2016.

<sup>3</sup>Fentanyl lozenges (PBS items 10684H, 10697B, 10698C, 10729Q, 10737D) were excluded as clinical indication on the PBS is for cancer treatment and palliative care only.

**PBS:** Pharmaceutical Benefits Scheme. **ATC:** Anatomical Therapeutic Chemical Classification System.

**Table 2. Pharmacological Cancer Treatment, Descriptions and ATC Codes.**

Description	Code
Antineoplastic and immunomodulating agents <sup>1</sup>	L01*

<sup>1</sup>Determined using 6 months of PBS data prior to home care episode (Rx-Risk-V). **ATC:** Anatomical Therapeutic Chemical Classification System.

**Suggested citation:** Registry of Senior Australians. Home Care Outcome Monitoring System Technical Specification – Chronic Opioid Use. Version 2.0. South Australian Health and Medical Research Institute. Adelaide, Australia; February 2024, 3 pages.

**Any enquires about, or comments on, this Technical Specification document should be directed to:**

Registry of Senior Australians (ROSA)  
South Australian Health and Medical Research Institute  
PO Box 11060, Adelaide SA 5001  
Ph: +61 (08) 8128 4662 Email: [ROSA.OMS@sahmri.com](mailto:ROSA.OMS@sahmri.com)  
Website: <https://rosaresearch.org/>

## References

1. Von Korff M, Saunders K, Thomas Ray G, Boudreau D, Campbell C, Merrill J, et al. De facto long-term opioid therapy for noncancer pain. *Clin J Pain.* 2008;24(6):521-7.